The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Role for Dipeptidyl Peptidase IV in Suppressing the Malignant Phenotype of Melanocytic Cells
Open accessAbstract
Dipeptidyl peptidase IV (DPPIV) is a cell surface peptidase expressed by normal melanocytes, epithelial cells, and other cells. Malignant cells, including melanomas and carcinomas, frequently lose or alter DPPIV cell surface expression. Loss of DPPIV expression occurs during melanoma progression at a stage where transformed melanocytes become independent of exogenous growth factors for survival. Tetracycline-inducible expression vectors were constructed to express DPPIV in human melanoma cells. Reexpressing DPPIV in melanoma cells at or below levels expressed by normal melanocytes induced a profound change in phenotype that was characteristic of normal melanocytes. DPPIV expression led to a loss of tumorigenicity, anchorage-independent growth, a reversal in a block in differentiation, and an acquired dependence on exogenous growth factors for cell survival. Suppression of tumorigenicity and reversal of a block in differentiation were dependent on serine protease activity, assessed using mutant DPPIV molecules containing serine→alanine substitutions. Surprisingly, dependence on exogenous growth factors was not dependent on serine protease activity. Reexpression of either wild-type or mutant DPPIV rescued expression of a second putative cell surface serine peptidase, fibroblast activation protein α, which can form a heterodimer with DPPIV. This observation suggests that rescue of fibroblast activation protein α may play a role in regulating growth of melanocytic cells. These results support the view that downregulation of DPPIV is an important early event in the pathogenesis of melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 4×
“Universität Heidelberg, Heidelberg, Germany) (16).”
BackgroundMethodInfluential
Cited by
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
“249–251 In vitro, DPP IV rapidly cleaves the N-terminal Tyr-Pro from NPY and PYY, resulting in NPY(3-36) and PYY(3-36).”
BackgroundInfluentialEmerging roles of proteases in tumour suppression
López-Otín, C., & Matrisian, L. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2228 · Cited by 802
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.-M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., & Wagtmann, N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120069197 · Cited by 538
Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
Hoek, K., Rimm, D. L., Williams, K. R., Zhao, H., Ariyan, S., Lin, A., Kluger, H. M., Berger, A. J., Cheng, E., Trombetta, E. S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0731 · Cited by 448
Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog
Rasmussen, H. B., Branner, S., Wiberg, F. C., & Wagtmann, N. (2003) · Nature Structural Biology · doi:10.1038/nsb882 · Cited by 424
Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas.
Hoek, K., Rimm, D., Williams, K., Zhao, H., Ariyan, S., Lin, A., Kluger, H., Berger, A., Cheng, E., Trombetta, E. S., et al. (2004) · Pigment Cell Research · doi:10.1111/j.1600-0749.2004.00175_12.x · Cited by 412
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yu, P., Fu, Y.-X., Weichselbaum, R. R., Rowley, D. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062056 · Cited by 359
The multifunctional or moonlighting protein CD26/DPPIV
Boonacker, E., & Van Noorden, C. J. F. (2003) · European Journal of Cell Biology · doi:10.1078/0171-9335-00302 · Cited by 337
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
GORRELL, M. D. (2005) · Clinical Science · doi:10.1042/cs20040302 · Cited by 334
Tumor-promoting functions of adenosine
Spychala, J. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00053-x · Cited by 284
Abbott, C. A., Yu, D. M. T., Woollatt, E., Sutherland, G. R., McCaughan, G. W., & Gorrell, M. D. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01617.x · Cited by 271
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Acharya, P. S., Zukas, A., Chandan, V., Katzenstein, A.-L. A., & Puré, E. (2006) · Human Pathology · doi:10.1016/j.humpath.2005.11.020 · Cited by 204
“There is also evidence to suggest that CD26 may facilitate expression of FAPa in melanocytes and that CD26 may affect both the differentiation and apoptotic program of melanocytes [24].”
BackgroundFazakas, C., Wilhelm, I., Nagyőszi, P., Farkas, A. E., Haskó, J., Molnár, J., Bauer, H., Bauer, H.-C., Ayaydin, F., Dung, N. T. K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020758 · Cited by 147
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K., & Gutierrez, J. A. (2016) · Biochemical Journal · doi:10.1042/bj20151085 · Cited by 123
Chemokine-protease interactions in cancer
Van Damme, J., Struyf, S., & Opdenakker, G. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.10.007 · Cited by 71
“In particular, DPPIV/CD26 expression on melanocytic cells is suppressing the malignant melanoma phenotype [29].”
BackgroundRepurposing drugs targeting metabolic diseases for cancer therapeutics
Pillai U, J., Ray, A., Maan, M., & Dutta, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103684 · Cited by 31
Metadata
- Authors
- Wesley, U. V., Albino, A. P., Tiwari, S., & Houghton, A. N.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1999-08-02
- Volume
- 190
- Issue
- 3
- Pages
- 311-322
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2159249597
- Cited by
- 190
- References
- 1
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.